PHASE-II EVALUATION OF DIGLYCOALDEHYDE, VP-16-213, AND THE COMBINATION OF METHYL-CCNU AND BETA-2'-DEOXYTHIOGUANOSINE IN PREVIOUSLY TREATED PATIENTS WITH COLORECTAL-CANCER - EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY (EST-1275)

1 January 1979

journal article
research article

Vol. 63 (8) , 1355-1357

Abstract

The Eastern Cooperative Oncology Group [USA] assessed the activity of diglycoaldehyde (DGA), VP-16-213 [vepeside] and the combination of methyl-CCNU [1-(2-chloroethyl)-3-4-methylcyclohexyl-1-nitrosourea] and .beta.-2''-deoxythioguanosine in previously treated patients with advanced colorectal cancer. Objective responses were seen in two of 40 evaluable patients receiving methylCCNU and .beta.-2''-deoxythioguanosine and in one of 35 patients receiving DGA. None of 33 patients responded to VP-16-213, but 1 death related to sepsis and bone marrow failure occurred. Survival of patients whose previous chemotherapy included a nitrosourea was markedly shortened compared to those who had not been exposed to nitrosoureas. With the possible exception of DGA, further treatment of patients with colorectal cancer with these therapies is not warranted.

This publication has 1 reference indexed in Scilit:

Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2′-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea. A phase II-III study of the eastern cooperative oncology group (EST 4273)
Cancer, 1978